drugset / Trial / NCT01850849

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

NCT01850849 ↗

Phase 1 Completed 23 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindOther

Summary

The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.

Timeline

Start
2013-05
Primary completion
2014-11
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 39652 Unknown — Topical

Indications